Dirk Jaeger Selected Research

Dirk Jaeger Research Topics

Disease

32	Neoplasms (Cancer) 04/2022 - 02/2007
13	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 11/2008
6	Neoplasm Metastasis (Metastasis) 10/2019 - 09/2011
4	Breast Neoplasms (Breast Cancer) 01/2019 - 01/2012
3	Adenocarcinoma 07/2017 - 01/2007
3	Carcinoma (Carcinomatosis) 11/2016 - 01/2012
3	Melanoma (Melanoma, Malignant) 02/2015 - 02/2007
2	Diarrhea 01/2017 - 01/2013
2	Hepatocellular Carcinoma (Hepatoma) 01/2014 - 01/2013
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2013 - 01/2012
2	Multiple Myeloma 03/2012 - 01/2012
2	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 10/2008 - 05/2007
1	Hypoxia (Hypoxemia) 12/2021
1	Lung Neoplasms (Lung Cancer) 01/2021
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021
1	Alopecia (Baldness) 01/2019
1	Hematologic Neoplasms (Hematological Malignancy) 01/2018
1	Bites and Stings (Sting) 01/2018
1	Prostatic Neoplasms (Prostate Cancer) 01/2017
1	Exanthema (Rash) 11/2016
1	Disease Progression 11/2016
1	Fatigue 11/2016
1	Hernia (Hernias) 07/2016
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2016
1	Starvation 11/2015
1	Measles 07/2013
1	Infections 07/2013
1	Neurologic Manifestations (Neurological Manifestations) 01/2013
1	Paresis (Hemiparesis) 01/2013
1	Seizures (Absence Seizure) 01/2013
1	Headache (Headaches) 01/2013
1	Vomiting 01/2013
1	Leukoencephalopathies 01/2013
1	Nausea 01/2013

Drug/Important Bio-Agent (IBA)

6	Proteins (Proteins, Gene)FDA Link 12/2021 - 01/2014
3	IpilimumabIBA 10/2018 - 02/2015
3	Biomarkers (Surrogate Marker)IBA 10/2018 - 01/2011
3	AntigensIBA 01/2018 - 10/2008
2	Maraviroc FDA Link 01/2022 - 10/2019
2	pembrolizumabIBA 01/2022 - 01/2021
2	NivolumabIBA 10/2018 - 11/2016
2	Pharmaceutical PreparationsIBA 01/2018 - 01/2014
2	VaccinesIBA 01/2018 - 10/2008
2	AntibodiesIBA 01/2018 - 11/2008
2	obatoclaxIBA 11/2015 - 01/2014
2	130-nm albumin-bound paclitaxelIBA 11/2014 - 08/2013
2	Neoplasm Antigens (Tumor Antigens)IBA 11/2009 - 02/2007
2	Monoclonal AntibodiesIBA 11/2008 - 10/2008
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 12/2021
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2021
1	Therapeutic UsesIBA 01/2021
1	FAPI-46IBA 01/2020
1	68Ga-FAPIIBA 01/2020
1	DNA (Deoxyribonucleic Acid)IBA 10/2019
1	vicrivirocIBA 10/2019
1	leronlimabIBA 10/2019
1	B7-H1 AntigenIBA 10/2018
1	entinostat (MS 275)IBA 01/2018
1	CTLA-4 AntigenIBA 01/2017
1	PlatinumIBA 11/2016
1	Lipase (Acid Lipase)FDA Link 11/2016
1	Amylases FDA Link 11/2016
1	ABT-737IBA 01/2016
1	Indicators and Reagents (Reagents)IBA 02/2015
1	Interleukin-10 (Interleukin 10)IBA 02/2015
1	Cysteine (L-Cysteine)FDA Link 11/2014
1	Trastuzumab (Herceptin)FDA Link 05/2014
1	Deubiquitinating EnzymesIBA 01/2014
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 09/2013
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 07/2013
1	Attenuated VaccinesIBA 07/2013
1	EnzymesIBA 07/2013
1	Cancer VaccinesIBA 07/2013
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 07/2013
1	InterferonsIBA 07/2013
1	Carcinoembryonic AntigenIBA 07/2013
1	Calcibiotic Root Canal SealerIBA 04/2013
1	CytokinesIBA 04/2013
1	Granzymes (Granzyme)IBA 04/2013
1	Tyrosine Kinase InhibitorsIBA 01/2013
1	Contrast MediaIBA 01/2013
1	Sorafenib (BAY 43-9006)FDA Link 01/2013
1	pazopanib FDA Link 01/2013
1	Immunomodulating AgentsIBA 03/2012
1	Thalidomide (Thalomid)FDA Link 03/2012
1	Angiogenesis InhibitorsIBA 01/2012
1	Keratins (Keratin)IBA 01/2011
1	Tumor Biomarkers (Tumor Markers)IBA 01/2011

Therapy/Procedure

17	Therapeutics 01/2021 - 11/2008
9	Drug Therapy (Chemotherapy) 11/2020 - 01/2007
6	Immunotherapy 01/2021 - 11/2009
1	Combined Modality Therapy 04/2022
1	Salvage Therapy 04/2022
1	Adjuvant Chemotherapy 01/2019
1	Castration 01/2017
1	Ostomy 07/2016
1	Chemoradiotherapy 07/2016
1	Transplantation 01/2014
1	Liver Transplantation 01/2014